Journal of Molecular and Cellular Cardiology, Год журнала: 2023, Номер 184, С. 13 - 25
Опубликована: Окт. 4, 2023
Язык: Английский
BMEMat, Год журнала: 2025, Номер unknown
Опубликована: Май 27, 2025
Abstract Extracellular vesicles (EVs) secreted by stem cells have become a promising cell‐free approach in regenerative medicine, with significant potential for the repair and treatment of musculoskeletal tissues disorders. However, limited bioactivity scalability EV production pose challenges commercial clinical translation. To overcome these challenges, researchers started exploring how cellular microenvironment can modulate characteristics enhance their therapeutic efficacy. While microenvironment's biochemical facets been primary focus prior investigations, influence biophysical factors on remains relatively underexplored. This review consolidates existing research investigating effects features function, particular emphasis applications regeneration. By providing comprehensive understanding impact EVs, this seeks to development effective strategies that harness power EVs large‐scale successful application therapies Ultimately, such insights could greatly assist patients who require innovative, treatments, thereby propelling advancements tissue engineering medicine.
Язык: Английский
Процитировано
0
Tissue Engineering Part A, Год журнала: 2023, Номер 29(23-24), С. 607 - 619
Опубликована: Авг. 11, 2023
Severe acute pancreatitis (SAP) is a common abdominal emergency with high mortality rate and lack of effective therapeutic options. Although mesenchymal stem cell (MSC) transplantation potential treatment for SAP, the mechanism remains unclear. It has been suggested that MSCs may act mainly through paracrine effects; therefore, we aimed to demonstrate efficacy extracellular vesicles (EVs) derived from human umbilical cord cells (UCMSCs) SAP. Na-taurocholate was used induce rat SAP model retrograde injection into biliopancreatic duct. After 72 h EVs transplantation, pancreatic pathological damage alleviated, along decrease in serum amylase activity pro-inflammatory cytokine levels. Interestingly, when UCMSCs were preconditioned 10 ng/mL tumor necrosis factor alpha (TNF-α) 48 h, obtained (named TNF-α-EVs) performed an enhanced efficacy. Furthermore, both animal cellular experiments showed TNF-α-EVs alleviated necroptosis acinar RIPK3/MLKL axis. In conclusion, our study demonstrated able enhance effect on by inhibiting compared normal EVs. This heralds be promising approach future. Mesenchymal (MSCs) are ideal seed repairing many diseases. Paracrine secretion important pathway achieve effects, MSC-derived have shown provide similar functions MSCs. However, severe this study, (UCMSC)-derived injury cells. More importantly, exerted The outcomes work evidence as cell-free therapy strategy
Язык: Английский
Процитировано
6
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(10), С. 5219 - 5219
Опубликована: Май 10, 2024
Interrupted blood flow in the brain due to ischemic injuries such as stroke or traumatic injury results irreversible damage, leading cognitive impairment associated with inflammation, disruption of blood-brain barrier (BBB), and cell death. Since BBB only allows entry a small class drugs, many drugs used treat ischemia other tissues have failed brain-related disorders. The administration mesenchymal stem (MSC)-derived extracellular vesicles (EVs) has shown promise improving functional recovery following cerebral by inducing vessel formation. To facilitate treatment approach, it is necessary develop bioprocesses that can produce therapeutically relevant MSC-EVs reproducible scalable manner. This study evaluated feasibility using stirred suspension bioreactors (SSBs) scale-up serum-free production pro-angiogenic under clinically physioxic conditions. It was found MSCs grown SSBs generated EVs stimulated angiogenesis microvascular endothelial cells, supporting use for application ischemia. These properties were impaired at higher confluency, outlining importance considering time harvest when developing manufacture EV populations.
Язык: Английский
Процитировано
2
Cytotherapy, Год журнала: 2024, Номер 26(12), С. 1532 - 1546
Опубликована: Июль 3, 2024
Human mesenchymal stromal cells (hMSCs) are a naturally adherent cell type and one of the most studied cellular agents used in therapy over last 20 years. Their mechanism action has been primarily associated with paracrine signalling, which contributed to an increase number studies focused on hMSC-related extracellular vesicles (EVs). In this study, we demonstrate for first time that human telomerase reverse transcriptase (hTERT) immortalised hMSCs can be adapted suspension culture, eliminating need microcarriers or other matrixes support growth. This novel line, named (S-hMSCs), doubling approximately 55 hours, growth rate 0.423 d−1. Regarding its immunophenotype characteristics, S-hMSCs retained close 90% CD73 CD105 expression levels, CD90 receptor being downregulated during adaptation process. An RNA sequencing analysis showed upregulation transcripts coding CD44, CD46 CD47 compared levels AT-hMSCs hTERT-hMSCs. The line herein established was able generate EVs using chemically defined medium formulation these nanoparticles averaging 150 nm size displaying markers CD63, CD81, TSG101, while not expressing negative marker calnexin. body evidence, combined visual confirmation EV presence transmission electron microscopy, demonstrates EV-producing capabilities S-hMSCs. provides platform process development, drug discovery translational field.
Язык: Английский
Процитировано
2
Journal of Molecular and Cellular Cardiology, Год журнала: 2023, Номер 184, С. 13 - 25
Опубликована: Окт. 4, 2023
Язык: Английский
Процитировано
5